Drug comprising at least one gestagen
US8361995B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Sep 3, 2009 |
| Grant date | Jan 29, 2013 |
| Priority date | — |
| Expiry date | Aug 18, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of at least one gestagen selected from the group consisting of chlormadinone acetate, 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxy-chlormadinone acetate) and 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3β-hydroxy-chlormadinone acetate) as gestagen component and optionally at least one oestrogen selected from the group consisting of ethinyl oestradiol, oestrone, oestriol as oestrogen component and oestradiol to produce a medicament for the treatment and/or prevention of melasma and optionally for simultaneous hormonal contraception or optionally for simultaneous hormone replacement for women.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.